Safety and Efficacy of Eltrombopag in Patients Undergoing Cord Blood or Haploidentical Bone Marrow Transplantation

Trial Profile

Safety and Efficacy of Eltrombopag in Patients Undergoing Cord Blood or Haploidentical Bone Marrow Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Bone marrow transplant rejection; Cord blood stem cell transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
    • 11 Jul 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
    • 19 Sep 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top